Usual Adult Dose for Prostate Cancer

VANTAS:
One 50 mg implant inserted subcutaneously in the inner aspect of the upper arm
Duration of therapy: The implant should be removed after 12 months.
NOTE: The implant is designed to allow for a few additional weeks of drug release to allow flexibility of medical appointments); when an implant is removed, another implant may be inserted to continue therapy.

Use: Vantas: Palliative treatment of advanced prostate cancer

Usual Pediatric Dose for Precocious Puberty

SUPPRELIN LA:
2 years and older:
One 50 mg implant inserted subcutaneously in the inner aspect of the upper arm
Duration of therapy: The implant should be removed after 12 months.
NOTE: When an implant is removed, another implant may be inserted to continue therapy.

Comments:

• Discontinuation of therapy should be considered at the discretion of the physician and at the appropriate time point for the onset of puberty (approximately 11 years for females and 12 years for males).

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Hypersensitivity to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs
• Pregnancy

Dialysis

Data not available

Other Comments

Storage requirements:
Vantas:

• Upon receipt, patients need to refrigerate the small carton containing the amber plastic pouch and glass vial (with the implant inside) until the day of insertion.
• The implant vial should not be opened until just before the time of insertion.
• Protect the implant from light.
• Do not freeze the implant.
• Store the implantation kit at room temperature only.

• The implant should be kept refrigerated in its sealed vial, pouch, and carton until needed for the procedure.
• Once removed from refrigeration, the vial containing the implant may remain at room temperature for up to 7 days before being used. If not used in that time, the packaged implant may again be refrigerated until the expiration date on the carton.
• Protect the implant from light.
• Do not freeze the implant.
• Store the implantation kit at room temperature only.

• The manufacturer product information should be consulted.

• Response to the drug should be monitored by measuring serum concentrations of testosterone and prostate-specific antigen (PSA) periodically, especially if the anticipated clinical or biochemical response to treatment have not been achieved. If a patient's response appears to be suboptimal, confirm that patient's serum testosterone concentration is at castrate level.

• Luteinizing hormone, follicle stimulating hormone, and estradiol or testosterone should be monitored at 1-month post implantation then every 6 months thereafter.
• During treatment, patients should be evaluated for evidence of clinical and biochemical suppression of central precocious puberty manifestations.
• Height (for calculation of height velocity) and bone age should be assessed every 6 to 12 months.

• This medication can cause an increase in hormone levels during the first week after the implant insertion, possibly causing a temporary worsening of symptoms or onset of new symptoms. Contact your doctor right away if you get any of these symptoms: new or worse bone pain, weakness or loss of feeling in your legs, blood in your urine, or trouble urinating.
• You may have skin reactions at the insertion site such as pain, bruising, tingling, and redness during and after the implant is inserted and removed. These usually go away without treatment within 2 weeks.
• This medication is not for use in women. It can harm the unborn baby in a pregnant woman and may cause a pregnant woman to have a miscarriage.

Frequently asked questions

• Is Supprelin LA the same as Lupron?
• How quickly does Supprelin LA work?